Skip to main content
. 2024 Sep 16;20(12):4922–4940. doi: 10.7150/ijbs.87829

Figure 2.

Figure 2

Deletion of TRPC5 attenuates gastrointestinal cancer metastasis. (A, B) Immunoblot analysis of TRPC5 protein expression in MKN-45 and DLD-1 cells modified by the CRISPR/Cas9 system. Data are expressed as means ± SD, ***P < 0.001 (vs. WT group). (C) Representative images from the transwell migration assay showing the migration of MKN-45 and DLD-1 cells treated with vehicle control or TRPC5 knockout (MKN-45TRPC5-/- and DLD-1TRPC5-/-). Random visual fields were selected. Scale bar: 500 μm. (D) Bar graph of migrated MKN-45 and DLD-1 cells in vehicle control and TRPC5 knockout groups. Data are expressed as means ± SD, ***P < 0.001 (vs. vehicle group). (E) Representative images from the wound healing assay in vehicle control and TRPC5 knockout groups. (F) Healing rates of MKN-45 and DLD-1 cells in vehicle control and TRPC5 knockout groups. Data are expressed as means ± SD, ***P < 0.001 (vs. vehicle group). (G) Schematic of animal study: 5 × 106 MKN-45 and DLD-1 (WT or TRPC5 knockout) cells were injected into BALB/c nude mice, and metastasis was assessed 30 days post-injection (n = 6 per group). (H, I) Analysis of liver metastasis in mice engrafted with MKN-45 and DLD-1 cells (WT or TRPC5 knockout) at day 30. Data are expressed as means ± SD, ***P < 0.001 (vs. MKN-45WT group), ###P < 0.001 (vs. DLD-1WT group).